G01N 2333/4716
Complement proteins
Official title: Complement proteins, e.g. anaphylatoxin, C3a, C5a
G01N2333/4716 (Complement proteins) appears on 157 US grants and 336 published applications in this corpus.
Search patents in G01N- Granted patents
- 157
- Published applications
- 336
- Assignees
- 195
- Inventors
- 585
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 3 |
| 2003 | 0 | 4 |
| 2004 | 1 | 1 |
| 2005 | 0 | 7 |
| 2006 | 0 | 7 |
| 2007 | 0 | 3 |
| 2008 | 4 | 6 |
| 2009 | 3 | 8 |
| 2010 | 2 | 9 |
| 2011 | 5 | 7 |
| 2012 | 4 | 13 |
| 2013 | 4 | 12 |
| 2014 | 6 | 8 |
| 2015 | 11 | 20 |
| 2016 | 8 | 30 |
| 2017 | 9 | 26 |
| 2018 | 12 | 17 |
| 2019 | 21 | 24 |
| 2020 | 23 | 16 |
| 2021 | 8 | 23 |
| 2022 | 8 | 10 |
| 2023 | 7 | 23 |
| 2024 | 9 | 29 |
| 2025 | 6 | 17 |
| 2026 | 4 | 13 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions, methods and kits for treating complement related disorders6 Oct 2026US 12,751,993 B2Trustees of Tufts College
- Isolated antigen binding protein binding to a complement protein C5 and a method of detecting thereof16 Jun 2026US 12,655,201 B2Longbio Pharma (Suzhou) Co., Ltd.
- Anti-complement factor C1q antibodies and uses thereof27 Jan 2026US 12,534,522 B2Annexon, Inc.
- Complement factor based affinity chromatography13 Jan 2026US 12,522,637 B2Hoffmann-La Roche Inc.
- Anti-complement factor C1q antibodies with single binding arms and uses thereof2 Dec 2025US 12,486,322 B2Annexon, Inc.
- Glycoprotein biomarkers for ovarian cancer diagnosis1 Oct 2026US 2026/0298932 A1Proseek Bio Pty Ltd.
- Diagnosis, monitoring or prognosis of type 2 diabetes, impaired glucose tolerance or prediabetes17 Sep 2026US 2026/0276653 A1FundacióN PúBlica Galega Instituto De InvestigacióN Sanitaria De Santiago De Compostela
- Depletion of high-abundance plasma proteins using in situ growth of metal-organic frameworks (mofs) for proteomic analysis and biomarker discovery10 Sep 2026US 2026/0266814 A1
- Methods for analyzing lung cancer associated proteomic markers27 Aug 2026US 2026/0251657 A1PrognomIQ, Inc.
- Methods for distinguishing lung cancer from non-cancer27 Aug 2026US 2026/0251663 A1PrognomIQ, Inc.
Most cited
By later US patents
- Method for assaying for natural killer, cytotoxic T-lymphocyte and neutrophil-mediated killing of target cells using real-time microelectronic cell sensing technology52US 7,468,255 B2ACEA Biosciences, Inc. · 2008
- Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration46US 7,816,497 B2University of Kentucky · 2010
- Anti-C5 antibodies37US 9,765,135 B2Chugai Seiyaku Kabushiki Kaisha · 2017
- Modulation of synaptic maintenance29US 8,148,330 B2The Board of Trustees of the Leland Stanford Junior University · 2012
- Diagnostics and therapeutics for macular degeneration-related disorders28US 7,351,524 B2University of Iowa Research Foundation · 2008